Advertisement

Understanding Atrial Cardiopathy: an Under-Recognized Contributor to Cardioembolic Stroke

  • Michelle C. JohansenEmail author
  • Henrique Doria De Vasconcellos
  • Rebecca F. Gottesman
Cerebrovascular Disorders (D Jamieson, Section Editor)
  • 73 Downloads
Part of the following topical collections:
  1. Topical Collection on Cerebrovascular Disorders

Abstract

Purpose of review

Ischemic stroke is the fifth leading cause of death in the world with cardioembolic stroke (CES) causing a disproportional amount of the morbidity and mortality associated with stroke. Atrial fibrillation (AF) is the leading cause of CES, and as the population ages, the incidence of CES is anticipated to rise. The importance of proper diagnosis and treatment of patients with embolic-appearing stroke is significant due to the burden of disease and the severity of the illness.

Recent findings

The past decade has seen an explosion of treatment options for patients with CES related to AF as well as better mechanisms by which to monitor and diagnose patients with AF. While optimal secondary prevention of stroke with anticoagulation in the setting of AF is known, what remains to be defined is the appropriate treatment of other types of strokes that appear embolic, but no source of the embolism is discovered.

Summary

In this article, we will review what is known about the diagnosis and treatment of CES, discuss the emergence of novel therapeutics and emphasize what must be investigated in the future to move the field forward, such as the emerging concept of atrial cardiopathy.

Keywords

Ischemic stroke Cardioembolic stroke Atrial cardiopathy Stroke treatment Stroke diagnosis 

Notes

Compliance with Ethical Standards

Conflict of Interest

Michelle C. Johansen reports grants from American Heart Association Mentored Clinical and Population Research Award and grants from NIH/ICTR KL2 Early Career Investigator Award, outside the submitted work. Henrique Doria De Vasconcellos declares no potential conflict of interest. Rebecca F. Gottesman is an Associate Editor for the journal Neurology.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    O’Carroll CB, Barrett KM. Cardioembolic stroke. Continuum (Minneap Minn). 2017;23(1, Cerebrovascular Disease):111–32.Google Scholar
  2. 2.
    Kasarskis EJ, O’Connor W, Earle G. Embolic stroke from cardiac papillary fibroelastomas. Stroke. 1988;19(9):1171–3.PubMedGoogle Scholar
  3. 3.
    Tice FD, Slivka AP, Walz ET, Orsinelli DA, Pearson AC. Mitral valve strands in patients with focal cerebral ischemia. Stroke. 1996;27(7):1183–6.PubMedGoogle Scholar
  4. 4.
    Castello R, Pearson AC, Labovitz AJ. Prevalence and clinical implications of atrial spontaneous contrast in patients undergoing transesophageal echocardiography. Am J Cardiol. 1990;65(16):1149–53.PubMedGoogle Scholar
  5. 5.
    Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke. 1991;22(8):983–8.PubMedGoogle Scholar
  6. 6.
    •• Meschia JF, Bushnell C, Boden-Albala B, Braun LT, Bravata DM, Chaturvedi S, et al. Guidelines for the primary prevention of stroke: A statement for healthcare professionals from the american heart association/american stroke association. Stroke. 2014;45(12):3754–832 Most recent guidelines addressing primary stroke prevention for patients with atrial fibrillation.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Gordon DL, Bendixen BH, Adams HP Jr, Clarke W, Kappelle LJ, Woolson RF. Interphysician agreement in the diagnosis of subtypes of acute ischemic stroke: Implications for clinical trials. TOAST Investig Neurol. 1993;43(5):1021–7.Google Scholar
  8. 8.
    Ay H, Benner T, Arsava EM, Furie KL, Singhal AB, Jensen MB, et al. A computerized algorithm for etiologic classification of ischemic stroke: the causative classification of stroke system. Stroke. 2007;38(11):2979–84.PubMedGoogle Scholar
  9. 9.
    Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Wolf ME, Hennerici MG. The ASCOD phenotyping of ischemic stroke (updated ASCO phenotyping). Cerebrovasc Dis. 2013;36(1):1–5.PubMedGoogle Scholar
  10. 10.
    Ay H, Furie KL, Singhal A, Smith WS, Sorensen AG, Koroshetz WJ. An evidence-based causative classification system for acute ischemic stroke. Ann Neurol. 2005;58(5):688–97.PubMedGoogle Scholar
  11. 11.
    •• Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. 2018 guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the american heart association/american stroke association. Stroke. 2018;49(3):e46–e110 Most recent guidelines regarding early management and workup for patients with ischemic stroke, with sections under revision.PubMedGoogle Scholar
  12. 12.
    Furie KL, Jayaraman MV. 2018 guidelines for the early management of patients with acute ischemic stroke. Stroke. 2018;49(3):509–10.PubMedGoogle Scholar
  13. 13.
    Timsit SG, Sacco RL, Mohr JP, Foulkes MA, Tatemichi TK, Wolf PA, et al. Early clinical differentiation of cerebral infarction from severe atherosclerotic stenosis and cardioembolism. Stroke. 1992;23(4):486–91.PubMedGoogle Scholar
  14. 14.
    Timsit SG, Sacco RL, Mohr JP, Foulkes MA, Tatemichi TK, Wolf PA, et al. Brain infarction severity differs according to cardiac or arterial embolic source. Neurology. 1993;43(4):728–33.PubMedGoogle Scholar
  15. 15.
    Kang DW, Chalela JA, Ezzeddine MA, Warach S. Association of ischemic lesion patterns on early diffusion-weighted imaging with TOAST stroke subtypes. Arch Neurol. 2003;60(12):1730–4.PubMedGoogle Scholar
  16. 16.
    Beghi E, Bogliun G, Cavaletti G, Sanguineti I, Tagliabue M, Agostoni F, et al. Hemorrhagic infarction: Risk factors, clinical and tomographic features, and outcome. A case-control study. Acta Neurol Scand. 1989;80(3):226–31.PubMedGoogle Scholar
  17. 17.
    •• Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation. 2014;129(8):837–47 Important statement summarizing the evidence that supports consideration of a new causal model for cardioembolic stroke.PubMedGoogle Scholar
  18. 18.
    Kamel H, Okin PM, Elkind MS, Iadecola C. Atrial fibrillation and mechanisms of stroke: time for a new model. Stroke. 2016;47(3):895–900.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–72.PubMedGoogle Scholar
  20. 20.
    Nattel S, Guasch E, Savelieva I, Cosio FG, Valverde I, Halperin JL, et al. Early management of atrial fibrillation to prevent cardiovascular complications. Eur Heart J. 2014;35(22):1448–56.PubMedGoogle Scholar
  21. 21.
    Barbarossa A, Guerra F, Capucci A. Silent atrial fibrillation: a critical review. J Atr Fibrillation. 2014;7(3):1138.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Reiffel JA, Verma A, Kowey PR, Halperin JL, Gersh BJ, Wachter R, et al. Investigators. Incidence of previously undiagnosed atrial fibrillation using insertable cardiac monitors in a high-risk population: the REVEAL AF study. JAMA Cardiol. 2017;2(10):1120–7.PubMedPubMedCentralGoogle Scholar
  23. 23.
    •• Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD, et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med. 2018;378(23):2191–201 Clinical trial investigating use of a DOAC in patients with ESUS.PubMedGoogle Scholar
  24. 24.
    Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.PubMedGoogle Scholar
  25. 25.
    Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.PubMedGoogle Scholar
  26. 26.
    Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials. Lancet. 2014;383(9921):955–62.PubMedGoogle Scholar
  27. 27.
    Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996;335(8):540–6.PubMedGoogle Scholar
  28. 28.
    January CT, Wann LS, Calkins H, Field ME, Chen LY, Furie KL, Cigarroa JE, Heidenreich PA, Cleveland JC Jr, Murray KT, Ellinor PT, Shea JB, Ezekowitz MD, Tracy CM, Yancy CW. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the heart rhythm society. Heart Rhythm. 2019 23.Google Scholar
  29. 29.
    Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, et al. Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomized non-inferiority trial. Lancet. 2009;374(9689):534–42.PubMedGoogle Scholar
  30. 30.
    Holmes DR Jr, Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK, et al. Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64(1):1–12.PubMedGoogle Scholar
  31. 31.
    Boersma LV, Schmidt B, Betts TR, Sievert H, Tamburino C, Teiger E, et al. EWOLUTION investigators. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. Eur Heart J. 2016;37(31):2465–74.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Tzikas A. Left atrial appendage occlusion with Amplatzer cardiac plug and amplatzer amulet: a clinical trials update. J Atr Fibrillation. 2017;10(4):1651.PubMedPubMedCentralGoogle Scholar
  33. 33.
    St. Jude Medical. AMPLATZER™ Amulet™ LAA Occluder Trial (Amulet IDE).; 2016 https://clinicaltrials.gov/ct2/show/NCT02879448.
  34. 34.
    Lakkireddy D, Afzal MR, Lee RJ, Nagaraj H, Tschopp D, Gidney B, et al. Short and long-term outcomes of percutaneous left atrial appendage suture ligation: results from a US multicenter evaluation. Heart Rhythm. 2016;13(5):1030–6.PubMedGoogle Scholar
  35. 35.
    Price MJ, Gibson DN, Yakubov SJ, Schultz JC, Di Biase L, Natale A, et al. Early safety and efficacy of percutaneous left atrial appendage suture ligation: results from the U.S. transcatheter LAA ligation consortium. J Am Coll Cardiol. 2014;64(6):565–72.PubMedPubMedCentralGoogle Scholar
  36. 36.
  37. 37.
    Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomized trials. Lancet. 2014;384(9958):1929–35.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al. Time to treatment with intravenous alteplase and outcome in stroke: An updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375(9727):1695–703.PubMedGoogle Scholar
  39. 39.
    Lees KR, Emberson J, Blackwell L, Bluhmki E, Davis SM, Donnan GA, et al. Stroke Thrombolysis Trialists’ Collaborators Group. Effects of alteplase for acute stroke on the distribution of functional outcomes: a pooled analysis of 9 trials. Stroke. 2016;47(9):2373–9.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Saver JL, Fonarow GC, Smith EE, Reeves MJ, Grau-Sepulveda MV, Pan W, et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA. 2013;309(23):2480–8.PubMedGoogle Scholar
  41. 41.
    Vaclavik D, Vilionskis A, Jatuzis D, Karlinski MA, Gdovinova Z, Korv J, et al. Clinical outcome of cardioembolic stroke treated by intravenous thrombolysis. Acta Neurol Scand. 2018;137(3):347–55.PubMedGoogle Scholar
  42. 42.
    Fuentes B, Martinez-Sanchez P, Alonso de Lecinana M, Egido J, Reig-Rosello G, Diaz-Otero F, et al. Efficacy of intravenous thrombolysis according to stroke subtypes: the Madrid Stroke Network Data. Eur J Neurol. 2012;19(12):1568–74.PubMedGoogle Scholar
  43. 43.
    Hsia AW, Sachdev HS, Tomlinson J, Hamilton SA, Tong DC. Efficacy of IV tissue plasminogen activator in acute stroke: does stroke subtype really matter? Neurology. 2003;61(1):71–5.PubMedGoogle Scholar
  44. 44.
    Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke RT-PA Stroke Study Group. N Engl J Med [Internet]. 1995;333(24):1581–7.Google Scholar
  45. 45.
    Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015;372(11):1009–18.PubMedGoogle Scholar
  46. 46.
    Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med [Internet]. 2015;372(1):11–20.Google Scholar
  47. 47.
    Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med [Internet]. 2015;372(11):1019–30.Google Scholar
  48. 48.
    Jovin TG, Chamorro A, Cobo E, de Miquel MA, Molina CA, Rovira A, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med [Internet]. 2015;372:2296–306.Google Scholar
  49. 49.
    Albers GW, Lansberg MG, Kemp S, Tsai JP, Lavori P, Christensen S, et al. A multicenter randomized controlled trial of endovascular therapy following imaging evaluation for ischemic stroke (DEFUSE 3). Int J Stroke. 2017;12(8):896–905.PubMedPubMedCentralGoogle Scholar
  50. 50.
    Chen CJ, Ding D, Starke RM, Mehndiratta P, Crowley RW, Liu KC, et al. Endovascular vs medical management of acute ischemic stroke. Neurology. 2015;85(22):1980–90.PubMedPubMedCentralGoogle Scholar
  51. 51.
    McDaniel MC. Anticoagulation after anterior myocardial infarction: Primum non nocere, or first do no harm. JACC Cardiovasc Interv. 2015;8(1 Pt B):163–5.PubMedGoogle Scholar
  52. 52.
    Moulson N, LaHaye SA, Bertrand OF, MacHaalany J. Prophylactic warfarin post anterior ST-elevation myocardial infarction: a systematic review and meta-analysis. Cardiovasc Revasc Med. 2017;18(8):559–64.PubMedGoogle Scholar
  53. 53.
    Gill R, Donahey E, Ruland S. Early administration of therapeutic anticoagulation following intravenous thrombolysis for acute cardiogenic embolic stroke caused by left ventricular thrombus: case report and topic review. Front Neurol. 2015;6:9.PubMedPubMedCentralGoogle Scholar
  54. 54.
    Ghadri JR, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, et al. International expert consensus document on takotsubo syndrome (part II): diagnostic workup, outcome, and management. Eur Heart J. 2018;39(22):2047–62.PubMedPubMedCentralGoogle Scholar
  55. 55.
    Heckle MR, McCoy CW, Akinseye OA, Khouzam RN. Stress-induced thrombus: prevalence of thromboembolic events and the role of anticoagulation in takotsubo cardiomyopathy. Ann Transl Med. 2018;6(1):4.PubMedPubMedCentralGoogle Scholar
  56. 56.
    Santoro F, Stiermaier T, Tarantino N, De Gennaro L, Moeller C, Guastafierro F, et al. Left ventricular thrombi in takotsubo syndrome: incidence, predictors, and management: Results from the GEIST (german italian stress cardiomyopathy) registry. J Am Heart Assoc. 2017;6(12):e006990.  https://doi.org/10.1161/JAHA.117.006990.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Homma S, Thompson JL, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR, et al. WARCEF Investigators. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med. 2012;366(20):1859–69.PubMedPubMedCentralGoogle Scholar
  58. 58.
    Massie BM, Collins JF, Ammon SE, Armstrong PW, Cleland JG, Ezekowitz M, et al. WATCH Trial Investigators. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the warfarin and antiplatelet therapy in chronic heart failure (WATCH) trial. Circulation. 2009;119(12):1616–24.PubMedGoogle Scholar
  59. 59.
    Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College Of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):1810–52.PubMedGoogle Scholar
  60. 60.
    Brambatti M, Connolly SJ, Gold MR, Morillo CA, Capucci A, Muto C, et al. ASSERT Investigators. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation. 2014;129(21):2094–9.PubMedGoogle Scholar
  61. 61.
    Kamel H, Bartz TM, Elkind MSV, Okin PM, Thacker EL, Patton KK, et al. Atrial cardiopathy and the risk of ischemic stroke in the CHS (cardiovascular health study). Stroke. 2018;49(4):980–6.PubMedPubMedCentralGoogle Scholar
  62. 62.
    Chen LY, Chung MK, Allen LA, Ezekowitz M, Furie KL, McCabe P, et al. Atrial fibrillation burden: Moving beyond atrial fibrillation as a binary entity: a scientific statement from the American Heart Association. Circulation. 2018;137(20):e623–44.PubMedGoogle Scholar
  63. 63.
    Benjamin EJ, D’Agostino RB, Belanger AJ, Wolf PA, Levy D. Left atrial size and the risk of stroke and death. Framingham Heart Study Circ. 1995;92(4):835–41.Google Scholar
  64. 64.
    Anaissie J, Monlezun D, Seelochan A, Siegler JE, Chavez-Keatts M, Tiu J, et al. Left atrial enlargement on transthoracic echocardiography predicts left atrial thrombus on transesophageal echocardiography in ischemic stroke patients. Biomed Res Int. 2016;2016:7194676.PubMedPubMedCentralGoogle Scholar
  65. 65.
    He J, Tse G, Korantzopoulos P, Letsas KP, Ali-Hasan-Al-Saegh S, Kamel H, et al. P wave indices and risk of ischemic stroke: a systematic review and meta-analysis. Stroke. 2017;48(8):2066–72.PubMedGoogle Scholar
  66. 66.
    Goette A, Kalman JM, Aguinaga L, Akar J, Cabrera JA, Chen SA, et al. EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. Heart Rhythm. 2017;14(1):e3–e40.PubMedGoogle Scholar
  67. 67.
    Al-Khatib SM, Allen LaPointe NM, Chatterjee R, Crowley MJ, Dupre ME, Kong DF, et al. Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review. Ann Intern Med. 2014;160(11):760–73.PubMedGoogle Scholar
  68. 68.
    Fisher M. Update on the early management of patients with acute ischemic stroke guidelines. Stroke. 2018;7:STROKEAHA118023990.Google Scholar
  69. 69.
    Pagan RJ, Parikh PP, Mergo PJ, Gerber TC, Mankad R, Freeman WD, et al. Emerging role of cardiovascular CT and MRI in the evaluation of stroke. AJR Am J Roentgenol. 2015;204(2):269–80.PubMedGoogle Scholar
  70. 70.
    Liu Y, Wang K, Su D, Cong T, Cheng Y, Zhang Y, et al. Noninvasive assessment of left atrial phasic function in patients with hypertension and diabetes using two-dimensional speckle tracking and volumetric parameters. Echocardiography. 2014;31(6):727–35.PubMedGoogle Scholar
  71. 71.
    Mochizuki A, Yuda S, Oi Y, Kawamukai M, Nishida J, Kouzu H, et al. Assessment of left atrial deformation and synchrony by three-dimensional speckle-tracking echocardiography: comparative studies in healthy subjects and patients with atrial fibrillation. J Am Soc Echocardiogr. 2013;26(2):165–74.PubMedGoogle Scholar
  72. 72.
    Obokata M, Negishi K, Kurosawa K, Tateno R, Tange S, Arai M, et al. Left atrial strain provides incremental value for embolism risk stratification over CHA(2)DS(2)-VASc score and indicates prognostic impact in patients with atrial fibrillation. J Am Soc Echocardiogr. 2014;27(7):709–716.e4.PubMedGoogle Scholar
  73. 73.
    Hur J, Kim YJ, Lee HJ, Ha JW, Heo JH, Choi EY, et al. Left atrial appendage thrombi in stroke patients: detection with two-phase cardiac CT angiography versus transesophageal echocardiography. Radiology. 2009;251(3):683–90.PubMedGoogle Scholar
  74. 74.
    Lee JM, Kim JB, Uhm JS, Pak HN, Lee MH, Joung B. Additional value of left atrial appendage geometry and hemodynamics when considering anticoagulation strategy in patients with atrial fibrillation with low CHA2DS2-VASc scores. Heart Rhythm. 2017;14(9):1297–301.PubMedGoogle Scholar
  75. 75.
    Gal P, Marrouche NF. Magnetic resonance imaging of atrial fibrosis: redefining atrial fibrillation to a syndrome. Eur Heart J. 2017;38(1):14–9.PubMedGoogle Scholar
  76. 76.
    Yaghi S, Liberman AL, Atalay M, Song C, Furie KL, Kamel H, et al. Cardiac magnetic resonance imaging: a new tool to identify cardioaortic sources in ischaemic stroke. J Neurol Neurosurg Psychiatry. 2017;88(1):31–7.PubMedGoogle Scholar
  77. 77.
    Baher A, Mowla A, Kodali S, Polsani VR, Nabi F, Nagueh SF, et al. Cardiac MRI improves identification of etiology of acute ischemic stroke. Cerebrovasc Dis. 2014;37(4):277–84.PubMedGoogle Scholar
  78. 78.
    Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O’Donnell MJ, et al. Cryptogenic Stroke/ESUS International Working Group. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014;13(4):429–38.PubMedGoogle Scholar
  79. 79.
    Yaghi S, Chang AD, Hung P, Mac Grory B, Collins S, Gupta A, et al. Left atrial appendage morphology and embolic stroke of undetermined source: a cross-sectional multicenter pilot study. J Stroke Cerebrovasc Dis. 2018;27(6):1497–501.PubMedGoogle Scholar
  80. 80.
    TCTMD. [Internet].Google Scholar
  81. 81.
    Geisler T, Poli S, Meisner C, Schreieck J, Zuern CS, Nagele T, et al. Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): rationale and study design. Int J Stroke. 2017;12(9):985–90.PubMedGoogle Scholar
  82. 82.
    •• National Library of Medicine. AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke (ARCADIA) [Internet]. ClinicalTrials.gov. Ongoing clinical trial that is using cardiac biomarkers to risk stratify patients with ESUS for treatment with apixaban versus aspirin.

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Michelle C. Johansen
    • 1
    Email author
  • Henrique Doria De Vasconcellos
    • 2
  • Rebecca F. Gottesman
    • 1
  1. 1.Department of NeurologyThe Johns Hopkins University School of MedicineBaltimoreUSA
  2. 2.Department of CardiologyThe Johns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations